PureTech Health PLC PRTC to Present at Two US Investor Conferences
February 21 2019 - 2:02AM
RNS Non-Regulatory
TIDMPRTC
PureTech Health PLC
21 February 2019
21 February 2019
PureTech Health plc
PureTech Health to Present at Two Upcoming US Investor
Conferences
PureTech Health plc (LSE: PRTC) ("PureTech Health"), an advanced
biopharmaceutical company developing novel medicines for
dysfunctions of the Brain-Immune-Gut (BIG) Axis, today announced
two presentations at upcoming investor conferences. Daphne Zohar,
co-founder and chief executive officer, will present at the SVB
Leerink Global Healthcare Conference in New York on Friday, 1
March, at 11:30 AM EST. Additionally, Joep Muijrers, PhD, chief
financial officer, will present at the Cowen and Company 39th
Annual Health Care Conference in Boston on Tuesday, 12 March, at
8:00 AM EST. Webcasts of both presentations will be available at
http://puretechhealth.com/investors under the Reports and
Presentations tab.
About PureTech Health
PureTech Health (LSE: PRTC) is an advanced biopharmaceutical
company developing novel medicines for dysfunctions of the
Brain-Immune-Gut (BIG) Axis. The Company has developed deep
insights into the connection between these systems and the
resulting role in diseases that have proven resistant to
established therapeutic approaches. By harnessing this emerging
field of human biology, PureTech Health is developing new
categories of medicines with the potential to have great impact on
people with serious diseases.
PureTech Health is advancing a rich pipeline of innovative
therapies with a capital efficient R&D model across its
Affiliates and its Internal labs. PureTech's Affiliates include
seven clinical-stage platforms with two product candidates that
have been filed with the US Food and Drug Administration (FDA) for
review and other novel pre-clinical programmes. These Affiliates
are developing ground-breaking platforms and therapeutic candidates
in collaboration with some of the world's leading experts.
PureTech's Internal research and development is centred on
tissue-selective immunomodulation for the treatment of oncology,
autoimmune, and CNS-related disorders, with a near-term focus on
targeting newly-discovered, foundational immunosuppressive
mechanisms in oncology and novel approaches that harness the
lymphatic infrastructure.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Forward Looking Statement
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, developments and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, those risks and uncertainties described in the risk factors
included in the regulatory filings for PureTech Health plc. These
forward-looking statements are based on assumptions regarding the
present and future business strategies of the company and the
environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press
release. Except as required by law and regulatory requirements,
neither the company nor any other party intends to update or revise
these forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact:
Investors EU media US media
Allison Mead Talbot Ben Atwell, Rob Winder Tom Donovan
+1 617 651 3156 +44 (0) 20 3727 1000 +1 857 559 3397
amt@puretechhealth.com ben.atwell@FTIconsulting.com tom@tenbridgecommunications.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAXBLLLKLFXBBQ
(END) Dow Jones Newswires
February 21, 2019 02:02 ET (07:02 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024